New Haven’s Melinta Therapeutics said it has raised $67 million to help it complete a Phase 3 clinical study of its investigational antibiotic for drug-resistant infections.
Ireland-based Malin Corp., which raised approximately $373 million in an initial public offering earlier this year, led the investment round. New York venture capital firm Vatera Healthcare Partners also participated, Melinta said.
Melinta hopes to get approvals for its drug, delafloxacin, to treat patients with acute bacterial skin and skin structure infections. The company said it is also considering applying to the U.S. Food and Drug Administration for approvals for delafloxacin to treat a type of bacterial pneumonia.
